title: Receptor occupation and pharmacokinetics of MPC-1304, a new Ca2+ channel antagonist, in spontaneously hypertensive rats.
abstract: MPC-1304, (+/-)-methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarbonate , is a novel 1,4-dihydropyridine Ca2+ channel antagonist with potent and long-lasting antihypertensive effects. We characterized the ex vivo and in vivo binding properties of MPC-1304 to Ca2+ channel antagonist receptors in myocardial, aortic and brain tissues of spontaneously hypertensive rats (SHR) by radioreceptor assay using [3H](+)-PN 200-110 ([5-methyl-3H](+)-PN 200-110 (4-(2,1,3-benzoxadiazol-4-yl)-1,4,-dihydro-5-methoxycarbonyl-2,6-d imethyl-1,4-dihydro-3-isopropylcarbonylpyridine-5-carboxylic acid methyl ester)). At 1 and 6 h after oral administration of MPC-1304 (10 mg/kg) in SHR, there was significant decrease (48%) in the number of [3H](+)-PN 200-110 binding sites (Bmax) in myocardial membranes compared to control values. The plasma concentration of MPC-1304 in SHR correlated significantly with the occupation by this drug of myocardial Ca2+ channel antagonist receptors. The in vivo specific binding of [3H](+)-PN 200-110 in particulate fractions of aorta of SHR was significantly reduced (74.8 and 37.9%, respectively) at 1 and 6 after oral administration of MPC-1304 (3 mg/kg), while the myocardial [3H](+)-PN 200-110 binding was decreased only at 1 h later. In these rats, there was little change in cerebral cortical [3H](+)-PN 200-110 binding. In conclusion, MPC-1304 exerted more selective and sustained occupation in vivo of Ca2+ channel antagonist receptors in vascular tissues of SHR than in those of myocardial and brain tissues.
authors: Pharmacology Research Laboratory, Taiho Pharmaceutical Co., Ltd., Kawauchi-cho, Tokushima 771-01, Japan.
authors: Y
authors: Y
authors: Nozawa
authors: H
authors: H
authors: Miyake
authors: S
authors: S
authors: Yamada
authors: S
authors: S
authors: Uchida
authors: T
authors: T
authors: Ohkura
authors: R
authors: R
authors: Kimura
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001011:Aorta / Q000187:drug effects; D001667:Binding, Competitive; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002540:Cerebral Cortex / Q000187:drug effects; D004095:Dihydropyridines / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D009543:Nifedipine / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR; D013997:Time Factors
chemical_list: D002121:Calcium Channel Blockers; D004095:Dihydropyridines; C059427:aranidipine; D009543:Nifedipine